QGC011program

A SYNERGISTIC EFFECT OF BAPAIs IN ASSOCIATION WITH OTHER ANTIHYPERTENSIVE DRUGS

Because a combination of treatments is generally required to control the blood pressure of patients, Quantum Genomics intends to develop and evaluate the clinical efficacy of combinations associating a BAPAI product with other anti-hypertensive agents.

Quantum Genomics has already demonstrated in hypertensive rats the therapeutic benefit of associating a BAPAI t with anti-hypertensive drugs acting on the peripheral renin-angiotensin system as the angiotensin converting enzyme-inhibitors (IEC) or the antagonists of angiotensin II receptors type 1 (ARA).

Quantum Genomics selected the QGC011 product, resulting from the association of QGC001 with an IEC and demonstrated on a hypertensive rat that the hypotensive effect produced by the QGC011 product is significantly higher than that of each component administered separately.